阿奇霉素联合辛伐他汀治疗慢性阻塞性肺疾病合并肺动脉高压的临床疗效

发布时间：2018-12-06 11:41

【摘要】：目的评价阿奇霉素联合辛伐他汀治疗慢性阻塞性肺疾病(COPD)合并肺动脉高压的临床疗效。方法 60例COPD合并肺动脉高压患者随机分为治疗组(n=30)和对照组(n=30)。对照组口服辛伐他汀20 mg,治疗组在对照组基础上加用阿奇霉素肠溶片0.25 g,2组疗程均为6个月。比较2组治疗前后血氧分压、血氧饱和度、6 min步行距离、用力肺活量(FVC)、一秒用力呼吸容积(FEV1)、肺收缩压、肺舒张压及C-反应蛋白(CRP)水平。观察2组患者治疗前后血脂和肝功能变化。结果治疗后,治疗组血氧分压、血氧饱和度、6 min步行距离、FVC及FEV1均显著高于治疗前(P0.05),肺收缩压、肺舒张压、CRP水平均显著低于治疗前(P0.05);治疗组三酰甘油(TG)、血清总胆固醇(TC)、低密度脂蛋白-胆固醇(LDL-C)显著低于对照组,高密度脂蛋白-胆固醇(HDL-C)显著高于对照组(P0.05)。2组肝功能比较差异无统计学意义(P0.05)。结论阿奇霉素联合辛伐他汀治疗COPD合并肺动脉高压疗效显著,且安全可靠。
[Abstract]:Objective to evaluate the efficacy of azithromycin combined with simvastatin in the treatment of chronic obstructive pulmonary disease (COPD) with pulmonary hypertension. Methods 60 patients with COPD complicated with pulmonary hypertension were randomly divided into treatment group (n = 30) and control group (n = 30). The control group was treated with simvastatin for 20 mg, plus azithromycin enteric-coated tablets for 6 months. Blood oxygen partial pressure, oxygen saturation, walking distance of 6 min, forced vital capacity (FVC), forced respiratory volume (FEV1), pulmonary systolic pressure, pulmonary diastolic pressure and C-reactive protein (CRP) were compared between the two groups before and after treatment. The changes of blood lipid and liver function were observed before and after treatment. Results after treatment, the levels of partial pressure of oxygen, saturation of blood oxygen, walking distance of 6 min, FVC and FEV1 in treatment group were significantly higher than those before treatment (P0.05), pulmonary systolic pressure, pulmonary diastolic pressure and CRP level were significantly lower than those before treatment (P0.05). The serum total cholesterol (TC),) low density lipoprotein cholesterol (LDL-C) of triacylglycerol (TG), in the treatment group was significantly lower than that in the control group. High density lipoprotein cholesterol (HDL-C) was significantly higher than the control group (P0.05). There was no significant difference in liver function between the two groups (P0.05). Conclusion Azithromycin combined with simvastatin is safe and reliable in the treatment of COPD with pulmonary hypertension.
【作者单位】：嘉兴市第一医院呼吸科;
【基金】：浙江省嘉兴市医学重点学科呼吸病学基金资助项目(04-z-011)
【分类号】：R563.9;R544.1

【参考文献】